Stämm, a Buenos Aires, Argentina-based early-stage biotechnology company, raised $17m in Series A funding.
The round was led by Varana Capital, with participation from Draper Associates, SOSV’s IndieBio, Decarbonization Consortium, Trillian LLC, New Abundance, Grid Exponential, VistaEnergy, Teramips, Cygnus Draper, Serenity Traders, and Dragones VC.
The company intends to use the funds to prepare for commercialization of its technology; further develop biopharma partnerships into pilot scale; enhance its operational infrastructure; and continue growing its 100+ person team, deepening its international presence.
Led by CEO Yuyo Llamazares, Stämm paires naturally occurring microfluidics and laminar flow together with 3D-printing to develop a next-generation biomanufacturing platform that will enable continuous and autonomous mammalian cell production.
FinSMEs
01/03/2022